IFP Advisors’s Nymox Pharmaceutical Corp NYMX Stock Holding History

IFP Advisors’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,500	Closed	-$8K	–	3612
2018 Q4	$8K	Hold	5,500	–	–	﹤0.01%	2640
2018 Q3	$14K	Hold	5,500	–	–	﹤0.01%	2673
2018 Q2	$18K	Buy	+5,500	New	+$21.1K	﹤0.01%	2542
2016 Q4	–	Sell	-440	Closed	-$1K	–	4181
2016 Q3	$1K	Hold	440	–	–	﹤0.01%	3802
2016 Q2	$1K	Buy	+440	New	+$1.08K	﹤0.01%	3718
2016 Q1	–	Sell	-540	Closed	-$2K	–	3602
2015 Q4	$2K	Buy	+540	New	+$1.81K	﹤0.01%	3391

Other funds holding NYMX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

IFP Advisors's NYMX Position: Q1 2019 in Review

IFP Advisors sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2019, closing a stake of 5,500 shares — an estimated $8K sold.

IFP Advisors first reported a position in NYMX in Q4 2015 and held it in 6 quarters. The position peaked at $18K in Q2 2018. 45 funds tracked by Wall St. Rank hold NYMX as of Q1 2019.

IFP Advisors reported no remaining Nymox Pharmaceutical Corp position as of Q1 2019 after selling out during the quarter.
IFP Advisors sold 5,500 Nymox Pharmaceutical Corp shares in Q1 2019, an estimated $8K.
IFP Advisors first reported a position in Nymox Pharmaceutical Corp in Q4 2015 and held it in 6 quarters.
IFP Advisors's Nymox Pharmaceutical Corp position peaked at $18K in Q2 2018.
45 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2019.

Based on IFP Advisors's 13F filing for Q1 2019, filed 15 May 2019.